Skip to main content
Premium Trial:

Request an Annual Quote

Gentel and Van Andel Receive Patent for GlycoProtein Profiling Technology

Premium

Proteomics firm Gentel Biosciences and Van Andel Research Institute said this week that they've been granted a US patent covering a technique for profiling changes in the glycosylation of proteins captured on an antibody array slide.

The patent, number 7,838,634, covers a "high-throughput method of screening for a biomarker indicative of a disease" and includes "methods utilizing a microarray to measure the glycan level of a protein."

Comprising roughly 80 percent of the protein biomarkers currently in clinical use, glycoproteins are a significant area of focus for biomarker research, and, VARI researcher Brian Haab said in a statement, "the ability to efficiently screen glycosylated variants of many proteins for use as biomarkers offers an unprecedented opportunity for discoveries of new glycan-based biomarkers."

Gentel owns exclusive rights to the technology through a licensing agreement it signed with VARI in 2006. It now plans to combine the glycan detection technology with more than 50 of its SilverQuant Antibody Array kits, which use chromogenic reagents for the detection of target proteins.

A patent for the technology is also pending in the European Union.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.